Evidence map›Paper›PMID 40690685›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Mechanistic modeling or machine learning for detecting variants of concern: Why not both?

Claus O Wilke, Luiz C Vieira

Abstract readComment
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Claus O WilkeDepartment of Integrative Biology, The University of Texas at Austin, Austin, TX 78712.ORCID 0000-0002-7470-9261
Luiz C VieiraDepartment of Integrative Biology, The University of Texas at Austin, Austin, TX 78712.ORCID 0009-0002-4195-1884

Funding

Enteroviral 2C protein as a therapeutic targetR01AI169462 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CRAIG E. CAMERON · 2022 to 2026
$3.8M
Investigating nanobodies to target multidrug resistant bacterial pathogensR01AI148419 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI DAVIES, BRYAN WILLIAM · 2020 to 2023
$2.8M
From microcin sequence to function: linking sequence variation to antimicrobial activityR56AI179799 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI DAVIES, BRYAN WILLIAM · 2024 to 2024
$726k
NIAID NIH HHS R01 AI148419NIAID NIH HHS R01 AI169462NIAID NIH HHS R56 AI179799
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40690685
PMCPMC12318215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.